ECI830

PreclinicalSmall molecule

Novartis

ECI830 is one of 28 small molecule programs targeting Breast Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Advanced HR+/HER2- Breast CancerRecruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Advanced HR+/HER2- Breast CancerPreclinical

Recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Gemzar

GGynecologic Oncology Group

Preclinical

22 3

Adenocard

Astellas

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Lexiscan

Astellas

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Acupan

YYonsei University

Preclinical

1 9

Vfend

PPrism Pharmaceuticals

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Advanced HR+/HER2- Breast Cancer

NCT06726148

Clinical

Trials by Indication[1]

Advanced HR+/HER2- Breast Cancer1 trial

An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors

Recruiting· Novartis logo

Novartis·Preclinical·NCT06726148·280 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ECI830. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ECI830 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ECI830. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Novartis

ECI830

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Advanced HR+/HER2- Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News